This site is intended for health professionals only
Wednesday 20 March 2019
Share |

Sobi obtains EC approval for new dosing frequency of Orfadin

Swedish Orphan Biovitrum International AB (Sobi™) has received confirmation by the European Commission (EC) approving a reduced dosing frequency for Orfadin® (nitisinone) from twice daily to once daily, in people with hereditary tyrosinemia type 1 (HT-1) with a body weight >20 kg.

 

People with hereditary tyrosinemia type 1 (HT-1) have problems breaking down an amino acid called tyrosine. Toxic by-products are formed and accumulate in the body, which can cause liver, renal and neurological complications.

 

Approximately 1000 persons worldwide are identified as living with HT-1 today.

 

Orfadin® (nitisinone) blocks the breakdown of tyrosine, thereby reducing the amount of toxic tyrosine by-products in the body. Patients must maintain a special diet in combination with Orfadin treatment as tyrosine is not adequately broken down. 

 

Before Orfadin became available, the survival rate in HT-1 was 29% after two years for children who developed symptoms before two months of age.1 After the introduction of Orfadin, the survival rate is 93% after two years in patients with treatment initiation before two months of age.2

 

“Sobi has a long-term commitment to improve the lives for people affected by hereditary tyrosinemia type 1, and the above modified dosing regimen is a further step in this journey”, says Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi.

 

The approval is based on the results of a clinical study in 18 people with HT-1, comparing a four week once-daily and four week twice daily dosing regimen. The study showed comparable blood-levels of nitisinone, as well as safety and efficacy for these two regimens. There was insufficient data (few people below 20 kg bodyweight were enrolled in the study) to be able to compare the two regimens in people below 20 kg. 

 

References

  1. van Spronsen FJ, Thomasse Y, Smit GP, et al. Hepatology. 1994;20(5):1187-1191
  2. Orfadin Product monograph 12/12/2016  (Submission Control No: 193226)

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine